Do immunoglobulin G and immunoglobulin E anti-l-asparaginase antibodies have distinct implications in children with acute lymphoblastic leukemia? A cross-sectional study

Galindo-Rodríguez, Gabriela; Jaime-Pérez, José C; Salinas-Carmona, Mario C; González-Díaz, Sandra N; Castro-Corona, Ángeles; Cavazos-González, Raúl; Treviño-Villarreal, Humberto; Heredia-Salazar, Alberto C; Gómez-Almaguer, David.
Rev. bras. hematol. hemoter ; 39(3): 202-209, July-Sept. 2017. tab, graf
Artículo en Inglés | LILACS | ID: biblio-898927

Documentos relacionados

  1. Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG-l-asparaginase product.
  2. A comprehensive review on microbial l-asparaginase: Bioprocessing, characterization, and industrial applications.
  3. A systematic review of recent trends in research on therapeutically significant L-asparaginase and acute lymphoblastic leukemia.
  4. Microbial L-asparaginase as a promising enzyme for treatment of various cancers.
  5. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study.
  6. Response surface methodology based optimized production, purification, and characterization of L-asparaginase from Fusarium foetens.
  7. In Silico Design of a Chimeric Humanized L-asparaginase.
  8. Unsatisfactory quality of E. coli asparaginase biogenerics in India: Implications for clinical outcomes in acute lymphoblastic leukaemia.
  9. Activity and toxicity of intramuscular 1000 iu/m<sup>2</sup> polyethylene glycol-E. coli L-asparaginase in the UKALL 2003 and UKALL 2011 clinical trials.
  10. Bacterial l-asparaginases for cancer therapy: Current knowledge and future perspectives.